CinCor Pharma - CINC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.25
  • Forecasted Upside: 38.81 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$34.04
▼ -1.38 (-3.90%)

This chart shows the closing price for CINC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CinCor Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CINC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CINC

Analyst Price Target is $47.25
▲ +38.81% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for CinCor Pharma in the last 3 months. The average price target is $47.25, with a high forecast of $64.00 and a low forecast of $30.00. The average price target represents a 38.81% upside from the last price of $34.04.

This chart shows the closing price for CINC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in CinCor Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2022Lifesci CapitalInitiated CoverageOutperform$64.00Low
9/9/2022Morgan StanleyBoost TargetOverweight$45.00 ➝ $60.00Low
8/21/2022Piper SandlerInitiated CoverageOverweightLow
8/9/2022Morgan StanleyBoost TargetOverweight$31.00 ➝ $45.00Low
7/21/2022OppenheimerBoost TargetOutperform$30.00 ➝ $35.00Low
7/15/2022Morgan StanleyBoost TargetOverweight$27.00 ➝ $31.00Low
2/1/2022Evercore ISIInitiated CoverageOutperformHigh
2/1/2022OppenheimerInitiated CoverageOutperform$30.00High
2/1/2022Morgan StanleyInitiated CoverageOverweight$27.00High
2/1/2022Jefferies Financial GroupInitiated CoverageBuy$30.00High
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
6/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/6/2022
  • 7 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/5/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
CinCor Pharma logo
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $34.04
Low: $33.84
High: $35.33

50 Day Range

MA: $30.59
Low: $22.40
High: $38.94

52 Week Range

Now: $34.04
Low: $13.00
High: $43.15

Volume

2,575 shs

Average Volume

345,925 shs

Market Capitalization

$1.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CinCor Pharma?

The following sell-side analysts have issued research reports on CinCor Pharma in the last twelve months: Evercore ISI, Jefferies Financial Group Inc., Lifesci Capital, Morgan Stanley, Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for CINC.

What is the current price target for CinCor Pharma?

4 Wall Street analysts have set twelve-month price targets for CinCor Pharma in the last year. Their average twelve-month price target is $47.25, suggesting a possible upside of 38.8%. Lifesci Capital has the highest price target set, predicting CINC will reach $64.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $30.00 for CinCor Pharma in the next year.
View the latest price targets for CINC.

What is the current consensus analyst rating for CinCor Pharma?

CinCor Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CINC will outperform the market and that investors should add to their positions of CinCor Pharma.
View the latest ratings for CINC.

What other companies compete with CinCor Pharma?

How do I contact CinCor Pharma's investor relations team?

The company's listed phone number is 844 531 1834 and its investor relations email address is 0. The official website for CinCor Pharma is www.cincor.com. Learn More about contacing CinCor Pharma investor relations.